T1	Disorder 19 44	lumbosacral radiculopathy
N1 	Reference T1 UMLS:C0154738	lumbosacral radiculopathy
T2	Pharmacological_substance 63 75	methotrexate
N1000 	Reference T2 MeSH:D008727	methotrexate
T3	Pharmacological_substance 118 130	methotrexate
N1001 	Reference T3 MeSH:D008727	methotrexate
T4	Pharmacological_substance 134 154	cytosine arabinoside
N1002 	Reference T4 MeSH:D003561	cytosine arabinoside
T5	Disorder 212 243	central nervous system leukemia
T6	Disorder 269 279	paraplegia
N2 	Reference T6 UMLS:C0030486	paraplegia
T8	Disorder 463 474	paraparesis
N3 	Reference T8 UMLS:C0221166	paraparesis
T9	Pharmacological_substance 493 505	methotrexate
N1003 	Reference T9 MeSH:D008727	methotrexate
T13	Pharmacological_substance 927 939	methotrexate
N1004 	Reference T13 MeSH:D008727	methotrexate
T14	Disorder 304 328	neurologic complications
N4 	Reference T14 UMLS:C0009566	neurologic complications
T7	Disorder 387 407	spinal cord toxicity
T12	Disorder 831 856	lumbosacral radiculopathy
N5 	Reference T12 UMLS:C0154738	lumbosacral radiculopathy
T15	Disorder 875 898	neurologic complication
N6 	Reference T15 UMLS:C0009566	neurologic complication
T16	Subject 247 255	children
T17	Subject 422 436	three children
T25	Pharmacological_substance 563 573	Gadolinium
N1005 	Reference T25 MeSH:D005682	Gadolinium
T28	Subject 653 667	three patients
T30	Subject 751 763	two patients
T32	Speculation_cue 809 816	suggest
T33	Disorder 774 789	severe symptoms
N7 	Reference T33 UMLS:C0436345	severe symptoms
T34	Disorder 676 735	elevation of cerebrospinal fluid immunoglobulin G synthesis
T10	Coreferring_mention 340 362	this mode of treatment
